AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8489107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg weekly
Number of subjects: 170
Study 8489107 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 170
Study 3829912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine HCl 150 mg
Number of subjects: 100
Study 3829912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine HCl 400 mg
Number of subjects: 100
Study 3829912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31930944 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated oxidised cellulose dressing (Surgicel, Ethicon, LLC, Puerto Rico)
Number of subjects: 24
Study 31930944 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate dressing (Biatain, Coloplast A/S, Denmark)
Number of subjects: 24
Study 28926413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive content measures (catastrophizing and self-efficacy)
Number of subjects: 165
Study 28926413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive process measure (mindfulness)
Number of subjects: 165
Study 27560291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser pretreatment followed by autologous transplantation and phototherapy
Number of subjects: 20
Study 27560291 — intervention group
Group type: COMPARATOR
Intervention: Autologous transplantation and phototherapy alone
Number of subjects: 20
Study 25008873 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed protein formula (eHF) for 10-14 days after birth, then standard preterm formula (SPF) until discharge (for infants <32 weeks gestational age)
Number of subjects: 328
Study 25008873 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preterm formula (SPF) initially, switched to eHF (7-14 days) if feeding intolerance at 6-8 days after birth (for infants 32-34 weeks gestational age)
Number of subjects: 328
Study 25008873 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (SPF)
Number of subjects: 328
Study 22126591 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF-BPBM
Number of subjects: 17
Study 22126591 — intervention group
Group type: COMPARATOR
Intervention: PRF
Number of subjects: 17
Study 20352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole alone (group B)
Number of subjects: 0
Study 20352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite alone (group C)
Number of subjects: 0
Study 20352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole combined with hydrotalcite (group D)
Number of subjects: 0
Study 20352149 — intervention group
Group type: COMPARATOR
Intervention: Observation (group A)
Number of subjects: 0
Study 18317187 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy followed by fusion with a Ray titanium cage
Number of subjects: 86
Study 18317187 — intervention group
Group type: COMPARATOR
Intervention: Discectomy alone
Number of subjects: 86
Study 17041689 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 50
Study 17041689 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 50
Study 14570681 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension with minimal inflation pressures (CHAMIP)
Number of subjects: 36
Study 14570681 — intervention group
Group type: COMPARATOR
Intervention: Normotensive anesthesia and conventional inflation pressures
Number of subjects: 36
Study 10917986 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein (SV)
Number of subjects: 752
Study 10917986 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical vein (HUV)
Number of subjects: 752
Study 10917986 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 752
Study 10917986 — intervention group
Group type: COMPARATOR
Intervention: HUV
Number of subjects: 752
Study 10917986 — intervention group
Group type: COMPARATOR
Intervention: PTFE
Number of subjects: 752
Study 8665202 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis (n=14)
Number of subjects: 30
Study 8665202 — intervention group
Group type: COMPARATOR
Intervention: Straight anastomosis (n=16)
Number of subjects: 30
Study 1572123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetrahydroaminoacridine (THA) and lecithin (75 to 200mg per day)
Number of subjects: 6
Study 2865021 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin intravenous infusion
Number of subjects: 6
Study 30449234 — intervention group
Group type: EXPERIMENTAL
Intervention: AR101 (peanut-derived investigational biologic oral immunotherapy)
Number of subjects: 496
Study 30449234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496
Study 30449234 — intervention group
Group type: EXPERIMENTAL
Intervention: AR101
Number of subjects: 496
Study 28372591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperation between geriatricians and general practitioners involving clinical geriatric assessment, medication review, and clinical follow-up over 24 weeks.
Number of subjects: 200
Study 28372591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperation between geriatricians and general practitioners
Number of subjects: 200
Study 26106623 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitizing medications (thiazolidinediones and metformin)
Number of subjects: 0
Study 26106623 — intervention group
Group type: COMPARATOR
Intervention: Insulin provision strategy (insulin and/or sulfonylureas)
Number of subjects: 0
Study 22998439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 62
Study 22998439 — intervention group
Group type: COMPARATOR
Intervention: Cancellous Screws
Number of subjects: 62
Study 22998439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcomes
Number of subjects: 62
Study 20878571 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy (Group A, n=22)
Number of subjects: 43
Study 20878571 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, n=21)
Number of subjects: 43
Study 18446859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus infection
Number of subjects: 15
Study 18446859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16174116 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hemodialysis (H/D)
Number of subjects: 93
Study 12590785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin intravaginally for three days
Number of subjects: 388
Study 12590785 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravaginally
Number of subjects: 388
Study 12590785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin intravaginally
Number of subjects: 388
Study 10535337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 23
Study 10535337 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 23
Study 8568137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8568137 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms/day
Number of subjects: 10
Study 8568137 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms/day
Number of subjects: 10
Study 8568137 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 800 micrograms/day
Number of subjects: 10
Study 1800388 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour overnight application of mepindolol
Number of subjects: 10
Study 1800388 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour application of mepindolol
Number of subjects: 10
Study 1800388 — intervention group
Group type: COMPARATOR
Intervention: Both application schemes (12-hour and 24-hour)
Number of subjects: 10
Study 6316120 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as an adjunct to chemotherapy and radiotherapy
Number of subjects: 13
Study 6316120 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an adjunct to chemotherapy and radiotherapy
Number of subjects: 13
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists assessing smoking status
Number of subjects: 408
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists advising smokers to quit
Number of subjects: 408
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists offering assistance via referral
Number of subjects: 408
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrists providing advice on smoking cessation medications
Number of subjects: 408
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers to intervention delivery
Number of subjects: 408
Study 29660046 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and advising likelihood based on practice location and training
Number of subjects: 408
Study 30132252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 35% (G1)
Number of subjects: 50
Study 30132252 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide 37% (G2)
Number of subjects: 50
Study 27013060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (with or without 180 mg loading dose)
Number of subjects: 82
Study 27013060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (with loading dose)
Number of subjects: 82
Study 27013060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid (without loading dose)
Number of subjects: 82
Study 27013060 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg QD
Number of subjects: 82
Study 24759300 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine phosphate-to-creatinine ratio
Number of subjects: 143
Study 24759300 — intervention group
Group type: EXPERIMENTAL
Intervention: New predictive equation including spot urine phosphate, creatinine, age, sex, and weight
Number of subjects: 143
Study 22242162 — intervention group
Group type: EXPERIMENTAL
Intervention: gag DNA alone
Number of subjects: 0
Study 22242162 — intervention group
Group type: EXPERIMENTAL
Intervention: gag DNA + IL-15
Number of subjects: 0
Study 22242162 — intervention group
Group type: EXPERIMENTAL
Intervention: gag DNA + high dose (1500 ug) IL-12
Number of subjects: 0
Study 22242162 — intervention group
Group type: EXPERIMENTAL
Intervention: gag DNA + intermediate dose (500 ug) IL-12
Number of subjects: 0
Study 19643320 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin reload (80 mg 12 h before intervention, with a further 40-mg pre-procedural dose)
Number of subjects: 383
Study 19643320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 19643320 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin reload
Number of subjects: 383
Study 17463217 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone for 5 days
Number of subjects: 32
Study 17463217 — intervention group
Group type: COMPARATOR
Intervention: Estradiol/drospirenone alone for 12 days
Number of subjects: 32
Study 17463217 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol/drospirenone plus indomethacin for 5 days
Number of subjects: 32
Study 15264655 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect group I (Therma Cure laboratory resin and Custom IQ resin)
Number of subjects: 60
Study 15264655 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect group II (Transbond XT and Sondhi Rapid Set)
Number of subjects: 60
Study 15264655 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-bonding group (Transbond XT)
Number of subjects: 60
Study 15264655 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo evaluation using Sondhi's indirect-bonding resin
Number of subjects: 60
Study 15264655 — intervention group
Group type: COMPARATOR
Intervention: In vivo evaluation using Therma Cure and Custom IQ
Number of subjects: 60
Study 12074455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-attachment dentures
Number of subjects: 64
Study 12074455 — intervention group
Group type: COMPARATOR
Intervention: Bar-clip dentures
Number of subjects: 64
Study 12074455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of IOD
Number of subjects: 64
Study 11313190 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Oral‐B‐7 EB 5 K, Braun AG, Kronberg, Germany)
Number of subjects: 50
Study 11313190 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B, Power Tip, Braun AG, Kronberg, Germany)
Number of subjects: 50
Study 11313190 — intervention group
Group type: COMPARATOR
Intervention: Control group (received instructions only once a year)
Number of subjects: 50
Study 9407819 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy for standardizing care of patients paralyzed with NMBAs
Number of subjects: 0
Study 9407819 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational tool (policy)
Number of subjects: 0
Study 9407819 — intervention group
Group type: EXPERIMENTAL
Intervention: NMBA order form
Number of subjects: 0
Study 8499815 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised reminder chart with explanation from a pharmacist
Number of subjects: 197
Study 8499815 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised reminder chart without explanation
Number of subjects: 197
Study 8499815 — intervention group
Group type: COMPARATOR
Intervention: No reminder chart with nurse counseling
Number of subjects: 197
Study 8499815 — intervention group
Group type: COMPARATOR
Intervention: No reminder chart with pharmacist counseling
Number of subjects: 197
Study 8499815 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised reminder chart
Number of subjects: 197
Study 8499815 — intervention group
Group type: COMPARATOR
Intervention: No reminder chart
Number of subjects: 197
Study 3554457 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0
Study 3554457 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 0
Study 3554457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TMP-SMZ and Pentamidine
Number of subjects: 0
Study 30159992 — intervention group
Group type: EXPERIMENTAL
Intervention: Public education program (Keep Watch @ Public Pools)
Number of subjects: 6930
Study 30159992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6930
Study 27876086 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of the rotator cuff with release of the superior transverse scapular ligament
Number of subjects: 42
Study 27876086 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic repair of the rotator cuff without release of the superior transverse scapular ligament
Number of subjects: 42
Study 24224648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate HistoScanning™ (PHS)
Number of subjects: 105
Study 24224648 — intervention group
Group type: COMPARATOR
Intervention: Standard TRUS-guided biopsies
Number of subjects: 105
Study 24224648 — intervention group
Group type: COMPARATOR
Intervention: Standard TTB
Number of subjects: 105
Study 24224648 — intervention group
Group type: COMPARATOR
Intervention: Standard pathological analysis of whole-mount prostatectomy specimens
Number of subjects: 105
Study 22101222 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher led presentation of information during trial introduction meetings
Number of subjects: 149
Study 21246854 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking (group A) - semen vaccariae fixed with plaster on various ear points, pressed 3 times daily for 5 mm each time, alternating sides every two days.
Number of subjects: 100
Study 21246854 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy of auricular point sticking and body acupuncture (group B) - same ear points as group A, plus body acupuncture at specific points (Zhongwan, Juanyuan, Tiansho, Zusanli, Sanyinjiao), applied once every two days.
Number of subjects: 100
Study 21246854 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of thin persons with spleen and stomach deficiency constitution vs. normal constitution.
Number of subjects: 100
Study 18381948 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cyclophosphamide/methotrexate/5‐fluorouracil (CMF) polychemotherapy
Number of subjects: 424
Study 15765393 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-D
Number of subjects: 317
Study 15765393 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-M
Number of subjects: 317
Study 15765393 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-C
Number of subjects: 317
Study 15765393 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS-A
Number of subjects: 317
Study 14527649 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40
Study 14527649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 40
Study 14527649 — intervention group
Group type: EXPERIMENTAL
Intervention: Home polysomnography
Number of subjects: 40
Study 14527649 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep assessments
Number of subjects: 40
Study 10214748 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid titration of pramipexole (full converted dose the day after stopping the former agonist)
Number of subjects: 16
Study 10214748 — intervention group
Group type: COMPARATOR
Intervention: Slow titration of pramipexole (up to 8 weeks to reach equivalent dosage)
Number of subjects: 16
Study 8607388 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of sinus rhythm
Number of subjects: 0
Study 8607388 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 0
Study 1888251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140
Study 1888251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31042578 — intervention group
Group type: EXPERIMENTAL
Intervention: Preloaded fiducial needles (PLNs)
Number of subjects: 44
Study 31042578 — intervention group
Group type: COMPARATOR
Intervention: Back-loaded fiducial needles (BLNs)
Number of subjects: 44
Study 27560455 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing Speed Training (PST)
Number of subjects: 62
Study 27560455 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 62
Study 25890597 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 73
Study 25890597 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (Control)
Number of subjects: 73
Study 24451865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone mineral (BOV, n=12)
Number of subjects: 24
Study 24451865 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphosilicate putty (PUT, n=12)
Number of subjects: 24
Study 24451865 — intervention group
Group type: COMPARATOR
Intervention: No graft (CTRL, n=6)
Number of subjects: 24
Study 21835837 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO (50% oxygen and 50% N(2)O)
Number of subjects: 36
Study 21835837 — intervention group
Group type: COMPARATOR
Intervention: Control group (50% oxygen and 50% nitrogen)
Number of subjects: 36
Study 19352247 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate injections (5 bone marrow aspirates and cyst injections)
Number of subjects: 5
Study 19352247 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injections (2 injections)
Number of subjects: 5
Study 19352247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow injection
Number of subjects: 5
Study 17584671 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface potential mapping (BSPM)
Number of subjects: 110
Study 15162891 — intervention group
Group type: EXPERIMENTAL
Intervention: SFGC 62.5 mg administered over 30 minutes
Number of subjects: 14
Study 15162891 — intervention group
Group type: EXPERIMENTAL
Intervention: SFGC 125 mg administered over 60 minutes
Number of subjects: 14
Study 15162891 — intervention group
Group type: EXPERIMENTAL
Intervention: SFGC 62.5 mg administered over 4 minutes (second dose)
Number of subjects: 14
Study 15162891 — intervention group
Group type: EXPERIMENTAL
Intervention: SFGC 125 mg administered over 7 minutes (second dose)
Number of subjects: 14
Study 12296486 — intervention group
Group type: EXPERIMENTAL
Intervention: Music distraction (attention diverting)
Number of subjects: 42
Study 12296486 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focusing (attending to procedural sensations)
Number of subjects: 42
Study 12296486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring (coping behavior during prior procedure)
Number of subjects: 42
Study 12296486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 9844330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at bedtime as maintenance therapy for one year
Number of subjects: 64
Study 9844330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7915853 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (41 pmol/kg/h)
Number of subjects: 6
Study 7915853 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY (50 pmol/kg/h)
Number of subjects: 6
Study 7915853 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 2491145 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative/didactic intervention
Number of subjects: 0
Study 2491145 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic/support intervention
Number of subjects: 0
Study 2491145 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 0
Study 2491145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 405433 — intervention group
Group type: EXPERIMENTAL
Intervention: APPG (4.8 X 10(6) units of aqueous procaine penicillin G intramuscularly plus 1 g of probenecid orally)
Number of subjects: 271
Study 405433 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP‐SMZ‐9 (nine tablets of trimethoprim‐sulfamethoxazole; 720 mg of TMP and 3,600 mg of SMZ, orally as a single dose)
Number of subjects: 271
Study 405433 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP‐SMZ‐12 (12 tablets of TMP‐SMZ; 960 mg of TMP and 4,800 mg of SMZ, orally as two doses of six tablets taken at a 6‐hr interval)
Number of subjects: 271
Study 405433 — intervention group
Group type: COMPARATOR
Intervention: APPG
Number of subjects: 271
Study 405433 — intervention group
Group type: COMPARATOR
Intervention: Neisseria gonorrhoeae treatment failures
Number of subjects: 271